Glucagon-like peptide-1 receptor agonists tied to higher thyroid cancer risk in first year of treatment
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...
Medscape2d
Drug-Drug Interactions With Glucagon-like Peptide-1 Receptor Agonists
Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...
pulmonologyadvisor1d
GLP-1 Receptor Agonists Tied to Risks and Benefits Beyond Weight Loss
For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...
HealthDay on MSN1d
GLP-1 RAs Tied to Higher Thyroid Cancer Risk in First Year of Treatment
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...
EurekAlert!1d
Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among us adults with overweight or obesity
In this cohort study, most patients with overweight or obesity discontinued glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy within 1 year, but those without type 2 diabetes had higher ...
Endocrinology Advisor3d
Select GLP-1 Receptor Agonists Reduce Risk of CKD Progression, ESKD, and MACE
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...
Endocrinology Advisor1d
GLP-1 Receptor Agonists May Have Broader Range of Benefits, Risks
With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...
Medscape2d
Empathy, Please: Be Sensitive Addressing Weight Management
Sometimes, the conversation doesn’t get past a handful of words, and just the attempt may threaten the patient-physician ...
HealthDay on MSN5d
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
(HealthDay News) — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online in ...
BMJ2d
GLP-1 agonists may raise risk of pulmonary aspiration during surgery, MHRA warns
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may ...
Scouted: ‘Nature’s Ozempic’? Experts Weigh in on the Budding GLP-1 Supplement Boom
Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...
pulmonologyadvisor1d
Websites Selling Compounded GLP-1 RAs Often Misinform Consumers
Websites that sell compounded GLP-1 RAs often partially inform or misinform consumers, including with respect to US FDA approval.